John E. Alessi

Life Sciences and Technology M&A

• Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, in its sale to Stryker Corporation, one of the world’s leading medical technology companies, by way of a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006.
• Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) in its merger with clinical-stage biotechnology company EIP Pharma Inc. (to be renamed “CervoMed”).
• Zyla Life Sciences in its merger with Assertio Therapeutics, Inc.
• Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, in its debt restructuring and pending acquisition of four FDA-approved, non-narcotic pain products from Iroko Pharmaceuticals, Inc.
• IntraLinks Holdings, Inc., in its auction and sale process resulting in a sale to Synchronoss Technologies, Inc., valued at approximately US$821 million.
• Novell, Inc., in responding to an unsolicited acquisition offer in a process that resulted in an auction and sale of the company in a concurrent patent sale and merger valued at US$2.2 billion.
• Gilead Sciences, Inc., in its acquisition of clinical program asset from a German private biopharmaceutical company in a transaction worth up to US$470 million.
• Broadcom Corporation in its US$165 million acquisition of a modem-related division of Japanese semiconductor manufacturer Renesas Electronics. 
• Vocus, Inc., in its auction and sale process resulting in a sale to GTCR valued at US$450 million. 
• Rhythmia Medical, Inc., in its US$265 million sale to Boston Scientific Corporation. 
• Broadcom Corporation in its US$3.7 billion acquisition of NetLogic Microsystems Inc.

Private Equity and Financial Services/Asset Management M&A

• North Haven Private Income Fund LLC (PIF) and SL Investment Corp. (SLIC), each a business development company externally managed by MS Capital Partners Adviser Inc., on their merger agreement for PIF to acquire SLIC.
• EnTrust Global on its acquisition from Franklin Templeton of the 65% interest that Legg Mason, Inc. holds in EnTrust Global.
• StoneCastle Partners in the sale of its subsidiary, StoneCastle Cash Insured Sweep, LLC (d/b/a interLINK), to Webster Financial Corporation’s principle bank subsidiary, Webster Bank, N.A.
• StoneCastle Asset Management and its parent StoneCastle Partners LLC on its sale of StoneCastle Asset Management’s Bank Investment Platform to ArrowMark Partners.
• Further Global Capital Management on its acquisition of U.S.-headquartered Payment Alliance International (PAI), the nation’s largest privately- held ATM provider.

Spin-Offs and Capital Market Transactions

• Biogen, Inc., in its spin-off of Bioverativ Inc., with an initial market capitalization of approximately US$4.8 billion.
• Citrix Systems, Inc., in its spin-off and sale of its “GoTo” software business to LogMeIn, Inc., valued at approximately US$1.8 billion.
• The RMR Group, Inc., in its public offering by way of a distribution through its public shareholders.

Includes matters handled at Dechert or prior to joining the firm.
 

• Challenges and Considerations to Raising Capital — Boston Biotech Forum (May 2024)